Cell therapy specialist Cytovia Therapeutics Inc and genome editing expert Cellectis SAS partner to develop iPSC-derived natural killer (NK) cell-based cancer therapies.
ADVERTISEMENT
Cellink AB will take over all shares of Ginolis Oy, a Finnish company focusing on diagnostics automation and advanced robotics solutions for medical and diagnostic industries.
CDMO Rentschler Biopharma will establish a Center of Excellence for cell and gene therapy through a new UK subsidiary Rentschler ATMP Ltd.
MicroRNA-based therapeutics developer InteRNA Technologies has closed an extended Series B round totaling €18.5m led by AurorA Science, an Italian biotech investment company.
The German Health Ministry has requested €6.2bn from the Federal Ministry of Finance to purchase up to 635 million additional doses of COVID-19 vaccines.
V-Bio Ventures has announced the first closing of its V-Bio Fund 2 at €78m. The fund is focussed on investments into early stage life sciences companies in Belgium and the EU.
·
The transatlantic Abingworth Bioventures 8 Fund has been closed at $464m to invest in US, UK and European life science companies.
As rapidly spreading mutants of SARS-CoV-2 are emerging, two Tuebingen-based vaccine developers will develop multivalent COVID-19 vaccines.
German CDMO Rentschler Biopharma is expanding cCMP production of CureVac NVs RNA-based COVID-19 vaccine candidate CVnCoV.